New Triple-Drug combo aims to control advanced breast cancer

NCT ID NCT05608252

First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 24 times

Summary

This study tests a new drug called VS-6766 combined with two standard drugs (abemaciclib and fulvestrant) in people with advanced HR+/HER2- breast cancer that has spread. The goal is to find the safest dose and see if the combination helps control the cancer. About 63 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana Farber Cancer Institite

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Massachusetts General Hospital Cancer Center

    WITHDRAWN

    Boston, Massachusetts, 02114, United States

Conditions

Explore the condition pages connected to this study.